Folliculitis decalvans (FD) is a rare, severe, inflammatory scarring (cicatricial) alopecia of the scalp characterized by recurrent painful pustules, follicular hyperkeratosis, crusting, and polytrichia—often referred to as "tufted hair," where multiple hair shafts emerge from a single dilated follicular orifice resembling a toothbrush (StatPearls NBK430735).
Because lesions frequently present with purulent drainage and intense perifollicular erythema, patients often experience extreme anxiety regarding whether the condition is a contagious infection that could spread to family members or partners. Furthermore, as painful pustular flares destroy surrounding scalp architecture and leave expanding patches of smooth, shiny scar tissue, patients urgently seek clarity on whether lost hair can regrow and which treatments reliably induce long-term remission.
Managing folliculitis decalvans requires a rapid, evidence-first clinical response. Because follicular destruction is irreversible once fibrosis takes hold, the overriding goal of therapy is not to chase cosmetic regrowth over scarred skin, but to aggressively halt active neutrophilic inflammation and preserve remaining terminal hair follicles.
Is Folliculitis Decalvans Contagious, and Will Hair Grow Back?
If you or a family member have been diagnosed with or suspect folliculitis decalvans, these fundamental clinical facts define the condition:
- Not Contagious: Folliculitis decalvans is NOT a contagious infection (British Association of Dermatologists). Although Staphylococcus aureus is routinely isolated from scalp pustules, FD is an altered, hyper-reactive host immune reaction to bacterial superantigens rather than a communicable disease. You cannot transmit FD to family members, partners, or coworkers through contact, shared towels, or bedding.
- Hair Regrowth Reality: Hair already lost to scarring alopecia cannot regrow naturally. The chronic neutrophilic infiltrate destroys the hair follicle stem cell niche in the follicular bulge, replacing functional pilosebaceous units with permanent fibrous scar tissue. Hair regrowth occurs only in perifollicular zones where follicles were inflamed but not fully destroyed.
- Gold-Standard Treatment (Clindamycin + Rifampicin): The best-evidenced systemic regimen is oral clindamycin 300 mg twice daily plus rifampicin 300 mg twice daily for 10 weeks. In published clinical series, a single 10-week course achieved complete clinical remission in 56% of patients (10 of 18), while repeated or extended courses increased total remission rates to 83% (15 of 18) (Rambhia et al., 2018, PMC6363910).
- Relapse & Maintenance: Without maintenance therapy, relapse rates after stopping antibiotics are high—up to 80% within months of completing a single course, as seen in the antimicrobial arms of the Tietze et al. comparison (relapse was far lower with oral isotretinoin). Long-term control requires maintenance strategies such as topical antiseptics, low-dose oral isotretinoin (0.4 mg/kg/day under specialist supervision), or intermittent anti-inflammatory regimens.
- Refractory Pipeline: For recalcitrant cases that fail oral antibiotics, advanced therapies including biologics (anti-IL-17A secukinumab, anti-TNF adalimumab), JAK inhibitors (baricitinib), and long-pulsed 1064 nm Nd:YAG laser epilation demonstrate high rates of disease stabilization (Fakhoury et al., 2024).
Why Does Folliculitis Decalvans Cause Permanent Scarring?
Understanding why folliculitis decalvans differs from benign scalp conditions helps explain why immediate medical intervention is essential.
In healthy hair follicles, the follicular epithelium maintains an immunologically privileged environment. In folliculitis decalvans, an abnormal cell-mediated immune response to colonizing Staphylococcus aureus strains triggers a massive influx of neutrophils into the upper and middle portions of the hair follicle (infundibulum and isthmus).
[Staph aureus Colonization & Superantigens]
│
▼
[Neutrophilic Infiltration & Intense Folliculitis]
│
▼
[Destruction of Follicular Bulge & Stem Cells]
│
▼
[Dermal Fibrosis & Permanent Scarring Alopecia]
As neutrophils release proteolytic enzymes and reactive oxygen species, the follicular wall ruptures. The hair shaft, now exposed directly to the dermis, acts as a foreign body, driving secondary granulomatous inflammation. Surrounding follicles fuse together beneath the surface, resulting in polytrichia (tufted hair)—where 5 to 20 individual hair shafts emerge through a single fibrotic pore.
Crucially, this inflammatory process targets the bulge region of the outer root sheath where epithelial stem cells reside. Once these stem cells are destroyed and replaced by collagenous fibrosis, the scalp loses its capacity to generate new hair follicles.
How Does Folliculitis Decalvans Differ From Other Scalp Conditions?
Because early treatment dictates hair preservation, distinguishing folliculitis decalvans from other scarring and non-scarring scalp disorders is critical:
| Clinical Feature | Folliculitis Decalvans (FD) | Lichen Planopilaris (LPP) | Central Centrifugal Cicatricial Alopecia (CCCA) | Seborrheic Dermatitis |
|---|---|---|---|---|
| Primary Infiltrate | Neutrophilic (pustular) | Lymphocytic (lichenoid) | Lymphocytic / Perifollicular | Malassezia yeast / non-scarring |
| Hallmark Sign | Follicular tufting (polytrichia), bouldering pustules, yellow crusting | Perifollicular erythema, violaceous scaling, lone hairs | Vertex expansion, shiny scalp, perifollicular halo | Greasy yellow scale, itch, no scarring |
| Scarring Status | Permanent scarring alopecia | Permanent scarring alopecia | Permanent scarring alopecia | Non-scarring (reversible) |
| Microbiology | S. aureus heavily cultured | Sterile immune-mediated | Sterile / traction-linked | Malassezia overgrowth |
| First-Line Therapy | Oral clindamycin + rifampicin | Hydroxychloroquine, topical/intralesional steroids | Topical steroids, doxycycline, gentle hair care | Topical antifungals, mild steroids |
If you are experiencing greasy scaling without pustules or hair loss, your condition may represent non-scarring scalp inflammation rather than a scarring alopecia. Conversely, if hair loss presents with violaceous scaling rather than active pustules, evaluation for lymphocytic scarring alopecias such as lichen planopilaris or central centrifugal cicatricial alopecia is warranted.
What Is the Evidence-Based Treatment Ladder for Folliculitis Decalvans?
Published clinical evidence and dermatology guidelines establish a structured treatment hierarchy for folliculitis decalvans (Rambhia et al., 2018).
First-Line: Oral Clindamycin (300mg BID) + Rifampicin (300mg BID) x 10 Weeks
│
▼
Second-Line: Tetracyclines (Doxycycline 100mg BID) OR Low-Dose Isotretinoin
│
▼
Third-Line: Biologics (Secukinumab, Adalimumab), JAK Inhibitors, 1064nm Nd:YAG Laser
1. First-Line Systemic Antibiotics: Clindamycin + Rifampicin
The combination of clindamycin and rifampicin is the cornerstone of FD therapy. Clindamycin provides potent anti-staphylococcal activity and reduces bacterial toxin production, while rifampicin penetrates intracellular reservoirs and biofilm-protected bacteria.
- Dosing: Clindamycin 300 mg twice daily + Rifampicin 300 mg twice daily for 10 weeks under clinical supervision.
- Efficacy: A pivotal study by Powell et al. demonstrated a 56% initial remission rate after one 10-week course, increasing to 83% following repeat courses for early relapses.
- Clinical Monitoring: Rifampicin induces liver enzymes and imparts an orange-red discoloration to bodily fluids (tears, urine, sweat). Baseline hepatic panel testing and complete blood count (CBC) are required before and during treatment.
2. Second-Line Options & Maintenance Therapies
When rifampicin is contraindicated or poorly tolerated, alternative oral regimens provide anti-inflammatory and antimicrobial benefit:
- Doxycycline / Minocycline: Doxycycline 100 mg twice daily for 3 to 6 months achieved clinical improvement or remission in 90% of patients (Vañó-Galván et al.), with a mean remission duration of 4.8 months.
- Azithromycin: Pulse dosing (500 mg daily for 3 consecutive days per week for 12 weeks) induced complete remission in small case series.
- Low-Dose Isotretinoin: Oral isotretinoin (0.4 to 0.5 mg/kg/day for at least 3 to 6 months under physician monitoring) reduces sebum production, shrinks follicular infundibula, and alters the microbial microenvironment. Courses shorter than 3 months carry a 66% relapse rate, whereas prolonged low-dose regimens serve as effective maintenance for refractory pustulation.
How Are Refractory Cases Treated With Biologics, JAK Inhibitors, and Laser?
For patients with severe, recalcitrant FD who experience immediate flares upon antibiotic withdrawal, advanced targeted immunomodulatory and procedural therapies offer high control rates.
1. Biologic & Targeted Immunomodulatory Pipeline
Recent literature highlights the role of Th17-driven inflammation and IL-17 cytokines in neutrophilic scarring alopecia:
- Secukinumab (Anti-IL-17A): Dosed at 300 mg weekly for 5 weeks followed by 300 mg every 2 to 4 weeks under specialist guidance. Published reports (Ismail & Sinclair, 2020; Moussa et al., 2022) confirm rapid cessation of pustules, resolution of pain, and long-term stabilization in patients refractory to multiple antibiotic courses.
- TNF-alpha Inhibitors (Adalimumab): Standard psoriasis/hidradenitis suppurativa dosing schedules have induced sustained remission in recalcitrant FD.
- JAK Inhibitors (Baricitinib, Tofacitinib): Dual JAK1/JAK2 inhibition targets downstream cytokine signaling in neutrophilic dermatoses. In a 2024 multicenter review by Fakhoury et al., baricitinib produced remission in all 4 treated patients (averaging 2.25 months), within a broader series in which TNF-alpha inhibitors achieved remission in 26 of 29 patients (89.6%).
2. Long-Pulsed 1064 nm Nd:YAG Laser Epilation
By destroying the hair shaft and follicular epithelium—the primary anatomical targets and foreign-body triggers of inflammation—laser hair removal can permanently halt the inflammatory cycle:
- Mechanism: Long-pulsed 1064 nm Nd:YAG lasers safely penetrate deep into the dermis while sparing epidermal melanin, making them ideal for both light and dark scalp skin.
- Clinical Evidence: Published case reports (Meesters et al.; Parlette et al.) document complete, long-term remission (1.5 years and 6 months post-treatment) following 8 to 9 monthly laser epilation sessions over active FD plaques.
Is a Hair Transplant Safe for Folliculitis Decalvans Scars?
Patients left with smooth, hairless scalp scars frequently inquire about surgical restoration via Follicular Unit Extraction (FUE) or Follicular Unit Transplantation (FUT).
[Active FD Inflammation] ──► Hair Transplant CONSTRAINDICATED (Graft Destruction)
│
▼
[12–24 Months Inactive] ──► Clinical + Biopsy Confirmation of Quiescence
│
▼
[Surgical Restoration] ──► Low-Density Test Grafting Over Scar Tissue
While surgical restoration is technically possible, proceeding prematurely carries severe risk:
- Absolute Contraindications: Hair transplantation must NEVER be performed during active or recent FD disease. Transplanting hair follicles into inflamed or subclinically active tissue triggers acute disease reactivation, destroying both the newly transplanted grafts and surrounding native hair.
- Quiescence Requirements: Dermatology consensus requires at least 12 to 24 months of complete, unmedicated clinical and histological remission before considering surgery. A scalp punch biopsy of the planned recipient area is mandatory to confirm the total absence of dermal neutrophilic infiltrates.
- Graft Survival Expectations: Scar tissue has reduced vascularity compared to healthy scalp skin. Graft survival rates in fibrotic scar tissue are lower, requiring conservative graft density placement and careful patient counseling regarding realistic aesthetic outcomes.
For a detailed review of surgical techniques and graft survival considerations, refer to our comprehensive guide on hair transplant candidacy in scarring alopecia.
What Is the Long-Term Patient Care and Flare Prevention Protocol?
Managing folliculitis decalvans extends beyond prescription medications. Patients must adopt a structured daily scalp hygiene protocol to minimize bacterial load and prevent secondary colonization:
- Antiseptic Scalp Cleansing: Incorporate chlorhexidine gluconate 4% or benzoyl peroxide 5% scalp washes into your routine 2 to 3 times weekly. Apply the wash gently to affected scalp regions, allowing it to remain in contact for 3 to 5 minutes before rinsing with tepid water.
- Avoidance of Mechanical Trauma: Refrain from aggressive scratching, picking, or squeezing scalp pustules or tufted hair bundles. Physical trauma disrupts the fragile follicular wall, releasing keratin debris into the dermis and triggering acute inflammatory flares.
- Sanitation of Environmental Contact Points: Change pillowcases every 2 to 3 days and wash all headwear, towels, and hairbrushes in hot water with antibacterial detergent. Avoid sharing personal grooming items with others.
- Monitoring for Early Flare Symptoms: Learn to recognize early warning signs of an impending flare—such as localized scalp burning, increased tenderness, or new papule formation. Contacting your dermatologist at the onset of symptoms allows for rapid initiation of topical antiseptics or short antibiotic pulses, preventing progression to irreversible scarring.
Frequently Asked Questions About Folliculitis Decalvans
Is folliculitis decalvans contagious to my family or intimate partners?
No. Folliculitis decalvans is not a contagious disease. Although Staphylococcus aureus bacteria are frequently cultured from scalp pustules, the condition is driven by an abnormal host immune hyper-reactivity to bacterial proteins rather than an active infection that can spread to others through touch or shared household items.
Why do I keep relapsing after completing a 10-week antibiotic course?
Rifampicin and clindamycin effectively suppress active bacterial colonization and neutrophilic inflammation, but they do not alter the underlying immune dysregulation. Once antibiotics are stopped, S. aureus recolonizes the scalp, triggering renewed inflammation in up to 80% of unmaintained patients. Long-term maintenance with topical antiseptics, low-dose isotretinoin, or periodic laser hair removal is required to sustain remission.
Can I get a hair transplant over folliculitis decalvans scar tissue?
Hair transplantation over folliculitis decalvans scars should be considered only after at least 12 to 24 months of total clinical and histological remission confirmed by scalp biopsy. Performing surgery while subclinical inflammation remains present will trigger disease reactivation and graft loss.
Sources
- StatPearls [Internet] — Tufted Hair Folliculitis (Folliculitis Decalvans): Saleh HM, Sathe NC. Tufted Hair Folliculitis. Treasure Island (FL): StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430735/
- Rambhia PH, et al. (2018) — Updates in therapeutics for folliculitis decalvans (systematic review): Rambhia PH, Conic RZ, Murad A, Atanaskova-Mesinkovska N, Piliang M, Bergfeld W. Updates in therapeutics for folliculitis decalvans: A systematic review with evidencebased analysis. J Am Acad Dermatol. 2019;80(3):794-801.e1. PMCID: PMC6363910
- Sillani C, et al. (2010) — Antimicrobial management of folliculitis decalvans: Sillani C, Bin Z, Ying Z, et al. Effective treatment of folliculitis decalvans using selected antimicrobial agents. Int J Trichology. 2010;2(1):20-23. PMCID: PMC3002406
- British Association of Dermatologists (BAD) — Folliculitis Decalvans Patient Information Leaflet: BAD Clinical Standards Unit. Folliculitis Decalvans Information Leaflet. Available from: https://www.skinhealthinfo.org.uk/condition/folliculitis-decalvans/
- Fakhoury T, et al. (2024) — Targeted Biologics in Recalcitrant Folliculitis Decalvans: Fakhoury T, Urban K, Ettefagh L, Nami N. Recalcitrant folliculitis decalvans treatment outcomes with biologics and small molecule inhibitors. Cutis. 2024;113(5):E32-E34. doi:10.12788/cutis.1023. Available from: https://mdedge.com/cutis/article/269375/hair-nails/recalcitrant-folliculitis-decalvans-treatment-outcomes-biologics-and
- DermNet NZ — Folliculitis Decalvans Clinical Overview: DermNet New Zealand Trust. Folliculitis decalvans. Available from: https://dermnetnz.org/topics/folliculitis-decalvans
- Cleveland Clinic — Folliculitis Decalvans Management: Cleveland Clinic Health Library. Folliculitis Decalvans. Available from: https://my.clevelandclinic.org/health/diseases/22784-folliculitis-decalvans
